evaluating the compatibility of treatment protocol for intravesical non-muscle invasive bladder cancer with the national clinical guideline at urmia imam khomeini hospital

Background: non-muscle-invasive bladder cancer (nmibc) is a heterogeneous disease characterized by a high risk of recurrence and progression. clinicians have various surgical and therapeutic options available for managing nmibc. objectives: this evaluated the alignment of treatment practices at all hospitals in urmia, a south-west province of iran, with current guidelines for treating nmibc. methods: this cross-sectional study included 134 patients with nmibc. demographic data, medical history, perioperative intravesical therapy, imaging results, cytology findings, and surgical procedures were collected. intravesical chemotherapy with mitomycin c, and post-surgical immunotherapy with bacilluscalmette-guérin (bcg) including induction and maintenance regimens and durations, were also recorded. treatment protocols were compared to established guidelines using ibm spss statistics version 21. results: the mean age of patients was 65 years, with 79.17% being male. adherence to clinical guidelines was 45.5% for obtaining a separate sample from the tumor base, 40.3% for urinary cytology, 67.9% for performing re-transurethral resection of bladder tumors (turbt), and 68.4% for performing re-turbt within the appropriate timeframe. among the patients indicated for re-turbt, only 30% underwent the procedure. mitomycin treatment was not used in 94.4% of low-risk patients. induction treatment with bcg was compatible with guidelines in 86.6% of patients. compliance with maintenance treatment was 69.8%, and adherence to the recommended duration was 55.2%. only 55% of patients with indications received maintenance treatment. overall treatment compliance with clinical guidelines was good in 19.4%, intermediate in 32.8%, and poor in 47.8%. conclusions: overall adherence to clinical guidelines for the management of nmibc was found to be suboptimal, particularly among low-risk patients.